Talphera, Inc.

Talphera, Inc.

TLPH · Nasdaq

Talphera, Inc. (TLPH) is a Drug manufacturers specialty generic company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Talphera, Inc. in 2026. The next earnings report is expected on November 16, 2026.

Earnings calendar

Next earnings date

16 Nov 2026

In 88 days

EPS estimate

-0.07

Revenue estimate

0

Past earnings

12 Aug 2026
EPS actual
-0.06 (+4.0%)
estimate -0.06
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
13 May 2026
EPS actual
-0.04 (+40.0%)
estimate -0.07
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
23 Mar 2026
EPS actual
-0.06 (+20.0%)
estimate -0.08
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
12 Nov 2025
EPS actual
-0.11 (+12.0%)
estimate -0.13
Revenue actual
1.0K
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Talphera beat consensus estimates on EPS, delivering EPS of -$0.06 versus an estimate of -$0.0625, while revenue met expectations at $0. In the prior quarter, EPS also came in ahead of expectations and revenue likewise met estimates.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. Talphera, Inc. was incorporated in 2005 and is headquartered in San Mateo, California.

Sector
Healthcare
Industry
Drug manufacturers specialty generic
Country
United States
Exchange
Nasdaq
CEO
Vincent J. Angotti
Employees
13
IPO date
11 Feb 2011
ISIN
US00444T2096
Website
talphera.com

Frequently asked questions

When does Talphera, Inc. (TLPH) next report earnings?

Talphera, Inc. (TLPH) is scheduled to report earnings on November 16, 2026.

What was Talphera, Inc.'s most recent earnings date?

Talphera, Inc. (TLPH) last reported earnings on August 12, 2026.

Where is Talphera, Inc. stock listed?

Talphera, Inc. (TLPH) is listed on Nasdaq.